| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology/Experimental Medicine |
From the CBR Institute for Biomedical Research (A.K.C., J.K., M.T.W., D.D.W.) and the Department of Pathology (A.K.C., J.K., D.D.W.), Harvard Medical School, Boston, Mass; the Centro di Riferimento Oncologico-Istituto di Ricerca e Cura a Carattere Scientifico (M.R.C., M.B., M.M., L.D.M.), National Cancer Institute, Aviano, Italy; and the International Centre for Genetic Engineering and Biotechnology (F.A.M., F.E.B., A.F.M.), Trieste, Italy.
Correspondence to Andrés F. Muro, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, I-34012, Trieste, Italy. E-mail muro{at}icgeb.org Denisa D. Wagner, CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, 800 Huntingdon Avenue, Boston, MA 02115. E-mail wagner@cbr.med.harvard.edu.
Abstract
Objective— Fibronectin (FN) plays an important role in the formation of stable arterial thrombi at the site of vascular injury. FN containing Extra Domain A (EDA+FN) is absent from normal plasma, but elevated plasma levels of EDA+FN are found in several pathological conditions. We hypothesized that EDA+FN plays a special role in thrombosis.
Methods and Results— We used mouse strains constitutively including (EDA+/+) or excluding (EDA–/–) the EDA domain in all tissues and plasma. Using a flow chamber and the ferric-chloride injury model we found that EDA+FN accelerates thrombosis both in vitro and in vivo at arterial shear rates. In EDA+/+ mice thrombi (>30 µm) grew faster when compared with EDAWT/WT (6.6±0.2 minutes versus 8.3±0.6 minutes, P<0.05) and the mean vessel occlusion time was shorter (9.9±0.4 minutes versus 14.6±1.7 minutes, P<0.05). However, the presence of EDA+FN affected neither single platelet adhesion to subendothelium nor thrombosis in veins. In addition, the mortality rate of EDA+/+ mice after collagen/epinephrine infusion was twice that of EDAWT/WT or EDA–/– mice.
Conclusions— Our findings reveal that EDA+FN has prothrombotic activity, and its presence in plasma may worsen pathological conditions in which this form is elevated.
EDA+FN is absent in normal plasma but elevated levels are observed in several pathological conditions. We found that EDA+FN has prothrombotic potential that is revealed at arterial shear rates. Thus the presence of EDA+FN in plasma may aggravate peripheral arterial disease, coronary artery disease, stroke, and other conditions.
Key Words: plasma fibronectin fibronectin splice variants isoforms arterial thrombosis intravital microscopy thromboembolism arterial and venous injury
Related Article:
Arterioscler Thromb Vasc Biol 2008 28: 203-204.
This article has been cited by other articles:
![]() |
A. Reheman, H. Yang, G. Zhu, W. Jin, F. He, C. M. Spring, X. Bai, P. L. Gross, J. Freedman, and H. Ni Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor Blood, February 19, 2009; 113(8): 1809 - 1817. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Mosher Adding Complexity to Fibronectin-Platelet Interactions Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 203 - 204. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |